[go: up one dir, main page]

BR9506452A - Heterocyclic compound preparation process of the heterocyclic compound pharmaceutical composition pharmaceutical composition suitable for the treatment of neurogenic inflammation process of treatment of neurogenic inflammation in an individual in need of such treatment and use of a heterocyclic compound - Google Patents

Heterocyclic compound preparation process of the heterocyclic compound pharmaceutical composition pharmaceutical composition suitable for the treatment of neurogenic inflammation process of treatment of neurogenic inflammation in an individual in need of such treatment and use of a heterocyclic compound

Info

Publication number
BR9506452A
BR9506452A BR9506452A BR9506452A BR9506452A BR 9506452 A BR9506452 A BR 9506452A BR 9506452 A BR9506452 A BR 9506452A BR 9506452 A BR9506452 A BR 9506452A BR 9506452 A BR9506452 A BR 9506452A
Authority
BR
Brazil
Prior art keywords
treatment
heterocyclic compound
pharmaceutical composition
neurogenic inflammation
individual
Prior art date
Application number
BR9506452A
Other languages
Portuguese (pt)
Inventor
Knud Erik Andersen
Uffe Bang Olsen
Hans Petersen
Frederik Christian Gronvald
Ursula Sonnewald
Tine Krogh Jorgensen
Henrik Sune Andersen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR9506452A publication Critical patent/BR9506452A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)

Abstract

The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.
BR9506452A 1994-01-04 1995-01-03 Heterocyclic compound preparation process of the heterocyclic compound pharmaceutical composition pharmaceutical composition suitable for the treatment of neurogenic inflammation process of treatment of neurogenic inflammation in an individual in need of such treatment and use of a heterocyclic compound BR9506452A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK1994 1994-01-04
DK129094 1994-11-09
PCT/DK1995/000002 WO1995018793A1 (en) 1994-01-04 1995-01-03 Novel heterocyclic compounds

Publications (1)

Publication Number Publication Date
BR9506452A true BR9506452A (en) 1997-09-02

Family

ID=26063135

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9506452A BR9506452A (en) 1994-01-04 1995-01-03 Heterocyclic compound preparation process of the heterocyclic compound pharmaceutical composition pharmaceutical composition suitable for the treatment of neurogenic inflammation process of treatment of neurogenic inflammation in an individual in need of such treatment and use of a heterocyclic compound

Country Status (31)

Country Link
US (8) US5595989A (en)
EP (1) EP0738262B1 (en)
JP (1) JP2944221B2 (en)
KR (1) KR100329450B1 (en)
CN (1) CN1083431C (en)
AT (1) ATE191909T1 (en)
AU (1) AU691858B2 (en)
BG (1) BG100692A (en)
BR (1) BR9506452A (en)
CA (1) CA2180238A1 (en)
CZ (1) CZ286109B6 (en)
DE (1) DE69516394T2 (en)
DK (1) DK0738262T3 (en)
ES (1) ES2147837T3 (en)
FI (1) FI114025B (en)
GR (1) GR3033967T3 (en)
HU (1) HUT75878A (en)
IL (1) IL112222A (en)
MY (1) MY113463A (en)
NO (1) NO306295B1 (en)
NZ (1) NZ277763A (en)
PE (1) PE45095A1 (en)
PL (1) PL180209B1 (en)
PT (1) PT738262E (en)
RU (1) RU2167152C2 (en)
SG (1) SG50602A1 (en)
SI (1) SI9520023A (en)
SK (1) SK88196A3 (en)
TW (1) TW300887B (en)
UA (1) UA47396C2 (en)
WO (1) WO1995018793A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110913A (en) * 1994-01-04 2000-08-29 Novo Nordisk A/S N-substituted azaheterocyclic carboxylic acids and esters thereof
MY113463A (en) * 1994-01-04 2002-03-30 Novo Nordisk As Novel heterocyclic compounds
US6239148B1 (en) 1994-01-04 2001-05-29 Novo Nordisk A/S N-substituted azaheterocyclic carboxylic acids and esters thereof
US5716949A (en) * 1995-04-07 1998-02-10 Novo Nordisk A/S Heterocyclic compounds
US5698551A (en) * 1995-04-07 1997-12-16 Novo Nordisk A/S Heterocyclic compounds
UA54385C2 (en) * 1995-04-07 2003-03-17 Ново Нордіск А/С N-substituted azaheterocyclic carboxylic acids and etHers thereof, a method for THEIR PREPARATION, a pharmaceutical composition and a method for treatment
US5962449A (en) 1995-04-07 1999-10-05 Novo Nordisk A/S Tricyclic compounds in treating hyperalgesic conditions and NIDDM
US5952352A (en) * 1995-04-07 1999-09-14 Novo Nordisk A/S Heterocyclic compounds
PL327445A1 (en) * 1995-12-15 1998-12-07 Novo Nordisk As Novel process
US6323206B1 (en) 1996-07-12 2001-11-27 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
ZA978792B (en) * 1996-10-04 1998-04-06 Novo Nordisk As N-substituted azaheterocyclic compounds.
WO1998015548A1 (en) * 1996-10-04 1998-04-16 Novo Nordisk A/S 1,4-disubstituted piperazines
CA2267500A1 (en) * 1996-10-04 1998-04-16 Novo Nordisk A/S N-substituted azaheterocyclic compounds
US6040318A (en) * 1997-06-25 2000-03-21 Novo Nordisk A/S Tricycle substituted with azaheterocyclic carboxylic acids
CA2307820C (en) 1997-10-27 2007-04-24 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
US6613905B1 (en) 1998-01-21 2003-09-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
CA2318088A1 (en) * 1998-01-21 1999-07-29 Yoshisuke Nakasato Chemokine receptor antagonists and methods of use therefor
US6509346B2 (en) 1998-01-21 2003-01-21 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
HUP0101320A3 (en) 1998-01-21 2002-11-28 Kyowa Hakko Kogyo Kk Benzo- and pyridobenzoxepine and -benzazepine derivatives and use thereof
ES2137136B1 (en) * 1998-05-18 2000-07-01 Esteve Labor Dr EMPLOYMENT OF ARYL (OR HETEROARIL) AZOLYL CARBINOL DERIVATIVES IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF NEUROGENIC INFLAMMATION.
US7271176B2 (en) * 1998-09-04 2007-09-18 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use thereof
US6468996B1 (en) * 1998-10-21 2002-10-22 Novo Nordisk A/S Substituted hetero-polycyclic compounds as PPARα and PPARγ activators
US6207682B1 (en) 1998-12-22 2001-03-27 Novo Nordisk A/S Modified release formulations containing (R)-1-(10,11-dihydro-5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1propyl)-3-piperidinecarboxylic acid
JP2002532551A (en) * 1998-12-22 2002-10-02 ノボ ノルディスク アクティーゼルスカブ New formulation
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
US7541365B2 (en) * 2001-11-21 2009-06-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US20040087642A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
TWI291467B (en) * 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor
WO2004112705A2 (en) * 2003-06-16 2004-12-29 Hypnion, Inc. Methods for treating sleep disorders
CA2662215A1 (en) 2006-09-01 2008-03-06 Immune Control, Inc. Novel compositions and methods for treatment of diseases related to activated lymphocytes
WO2017040963A1 (en) 2015-09-03 2017-03-09 Forma Therapeutics, Inc. [6,6] fused bicyclic hdac8 inhibitors
JP2020526592A (en) 2017-07-13 2020-08-31 トニックス ファーマシューティカルズ ホールディング コーポレーション Cyclobenzaprine analogs and amitryptylene analogs
CN115850232B (en) * 2023-02-16 2023-05-26 广州佳途科技股份有限公司 A kind of preparation method and application of flupenthixol EP impurity H

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3316249A (en) * 1967-04-25 Part a.xmethyl n n-(z-diethylaminoethyl)-n-(z- nitrophenyl) anthranilate hydrochloride
US2931810A (en) * 1960-04-05 Phenothiazine derivatives
BE552557A (en) * 1955-11-15
NL108827C (en) * 1956-04-09
BE562299A (en) * 1956-11-15
BE560750A (en) * 1957-07-26
NL222355A (en) * 1957-11-05
FR1216268A (en) * 1958-04-24 1960-04-25 Rhone Poulenc Sa New phenothiazine derivatives with a piperidine chain substituted by an amide function and their preparation
US3069432A (en) * 1961-02-20 1962-12-18 Olin Mathieson 5-(aminoalkyl)-5, 11-dihydrodibenzo-oxazepines
DE1159954B (en) * 1961-11-25 1963-12-27 Boehringer & Soehne Gmbh Process for the production of new 10- (alkoxypiperidinopropyl) -phenthiazines and their salts
US3157658A (en) * 1963-07-05 1964-11-17 Searle & Co 1-carbalkoxy-4-(9-xanthenyl) piperazines and related compounds
BE664609A (en) * 1964-06-01
US3886170A (en) * 1974-04-22 1975-05-27 Robins Co Inc A H 5-(3-)SUBSTITUTED-10,11-DIHYDRO-5H-dibenz{8 b,f{9 azepines
US4888335A (en) * 1988-07-25 1989-12-19 Mcneilab, Inc. 3-alkoxy-2-aminopropyl heterocyclic amines and their use as cardiovascular agents
US5296602A (en) * 1991-03-18 1994-03-22 Sloan-Kettering Institute For Cancer Research Multisubstituted 1-hydroxy-9-acridones with anticancer activity
US5420123A (en) * 1992-12-21 1995-05-30 Bristol-Myers Squibb Company Dibenzodiazepine endothelin antagonists
US5538986A (en) * 1993-12-06 1996-07-23 Schering Corporation Tricyclic derivatives, compositions and methods of use
MY113463A (en) * 1994-01-04 2002-03-30 Novo Nordisk As Novel heterocyclic compounds

Also Published As

Publication number Publication date
IL112222A (en) 1999-12-31
BG100692A (en) 1997-09-30
US5688788A (en) 1997-11-18
US5693649A (en) 1997-12-02
FI962749L (en) 1996-09-04
FI962749A0 (en) 1996-07-04
WO1995018793A1 (en) 1995-07-13
US5595989A (en) 1997-01-21
HUT75878A (en) 1997-05-28
US5712292A (en) 1998-01-27
DK0738262T3 (en) 2000-09-04
SI9520023A (en) 1997-04-30
AU691858B2 (en) 1998-05-28
US5668129A (en) 1997-09-16
TW300887B (en) 1997-03-21
US6043239A (en) 2000-03-28
SG50602A1 (en) 1998-07-20
JPH09507239A (en) 1997-07-22
EP0738262A1 (en) 1996-10-23
NO306295B1 (en) 1999-10-18
CN1083431C (en) 2002-04-24
GR3033967T3 (en) 2000-11-30
RU2167152C2 (en) 2001-05-20
JP2944221B2 (en) 1999-08-30
HU9601842D0 (en) 1996-09-30
NZ277763A (en) 2001-11-30
CN1142226A (en) 1997-02-05
FI114025B (en) 2004-07-30
CA2180238A1 (en) 1995-07-13
AU1311095A (en) 1995-08-01
PL180209B1 (en) 2001-01-31
US5795888A (en) 1998-08-18
EP0738262B1 (en) 2000-04-19
CZ286109B6 (en) 2000-01-12
ES2147837T3 (en) 2000-10-01
US5721254A (en) 1998-02-24
IL112222A0 (en) 1995-03-30
KR100329450B1 (en) 2002-10-04
PE45095A1 (en) 1995-12-18
NO962811L (en) 1996-09-04
UA47396C2 (en) 2002-07-15
DE69516394T2 (en) 2000-10-26
NO962811D0 (en) 1996-07-03
SK88196A3 (en) 1997-06-04
PT738262E (en) 2000-10-31
DE69516394D1 (en) 2000-05-25
CZ192196A3 (en) 1997-05-14
MY113463A (en) 2002-03-30
ATE191909T1 (en) 2000-05-15

Similar Documents

Publication Publication Date Title
BR9506452A (en) Heterocyclic compound preparation process of the heterocyclic compound pharmaceutical composition pharmaceutical composition suitable for the treatment of neurogenic inflammation process of treatment of neurogenic inflammation in an individual in need of such treatment and use of a heterocyclic compound
MX9707531A (en) Novel heterocyclic compounds.
EA200400944A1 (en) SUBSTITUTED TETRACYCLINE DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING THE SUBJECT WITH THEIR USE
BR0113039A (en) Compound or a physiologically acceptable salt or solvate thereof, use thereof, pharmaceutical composition, aerosol pharmaceutical formulation, method for treating a human or animal subject with an antiinflammatory and / or allergic condition, and process for preparing a compound
ATE117894T1 (en) STABILIZED NITROGEN OXIDE/PRIMARY AMINE COMPLEXES FOR USE AS CARDIOVASCULAR ACTIVES.
IT1288290B1 (en) SELF-LETICULATED HYALURONIC ACID AND RELATED PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ARTHROPATHIES
EA200201271A1 (en) INHIBITORS 11-BETA-HYDROXYSTEROID DEGYDROGENASE TYPE 1
AR032136A1 (en) USEFUL ESPIROHETEROCICLIC COMPOUNDS AS REVERSIBLE CISTEINE-PROTEASES INHIBITORS
AR002751A1 (en) TETRAHYDROFURAN ANTIFUNGALS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THE USE OF THE COMPOUNDS TO PREPARE USEFUL PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FUNGAL INFECTIONS
BR9712202A (en) Compound, process for preparing the same, pharmaceutical composition, process for the treatment of neurogenic inflammation in an individual in need of this treatment, and use of the compound.
DK1167354T3 (en) Racemic hypersensitivity A
BRPI0407652A (en) method for enhancing the effectiveness of an active agent, composition and method for producing the composition
NO20001169L (en) 6.9-bridge erythromycin derivatives
BR9813319A (en) Compound, pharmaceutical composition for treating bacterial infections, and processes for treating bacterial infections and for preparing a compound
DE69615169D1 (en) N-substituted azaheterocyclic carboxylic acids and their alkyl esters
AR046874A1 (en) NEW METHODS
AR044014A1 (en) PHARMACEUTICAL COMPOSITIONS FOR INTRANASAL ACID ADMINISTRATION [2- (8,9-DIOXO-2, 6-DIAZABICICLO [5.2.0) NON-1 (7) -EN-2-IL) RENTAL] -PHOSPHONIC AND DERIVATIVES AND METHODS OF USE FROM THE SAME
AR043186A1 (en) INDOZOLAMIDS PROVIDED WITH ANALGESIC ACTIVITY, METHOD OF PREPARATION OF THE SAME AND PHARMACEUTICAL COMPOUND THAT INCLUDES THEM
AU5100496A (en) Novel heterocyclic compounds
IL117812A0 (en) N-substituted heterocyclic compounds their preparation and pharmaceutical compositions containing them
CO5271694A1 (en) BETA DI-REPLACED INHIBITORS OF METALOPROTEASES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCEDURES FOR APPLICATION
EA200400709A1 (en) INHIBITORS 11-BETA-HYDROXYSTEROID DEGYDROGENASE TYPE 1
BR0214644A (en) Use of 4-oxobutanoic acid derivatives in the treatment of inflammation.

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
FF Decision: intention to grant
FG9A Patent or certificate of addition granted
B24C Patent annual fee: request for for restoration

Free format text: REFERENTE A 12A, 13A, 14A E 15A ANUIDADES.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2047 DE 30/03/2010.